Endotracheal Aerosolization Device for Laboratory Investigation of Pulmonary Delivery of Nanoparticle Suspensions: In Vitro and in Vivo Validation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1543-8392 (Electronic) Linking ISSN: 15438384 NLM ISO Abbreviation: Mol Pharm Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, DC : American Chemical Society, c2004-
    • Subject Terms:
      Nebulizers and Vaporizers*; Budesonide/*administration & dosage ; Drug Carriers/*chemistry ; Fluorescent Dyes/*administration & dosage ; Lung/*metabolism; Administration, Inhalation ; Animals ; Budesonide/pharmacokinetics ; Drug Compounding/methods ; Feasibility Studies ; Intravital Microscopy/methods ; Lipids/chemistry ; Male ; Microscopy, Fluorescence/methods ; Nanoparticles/chemistry ; Particle Size ; Rats ; Rats, Sprague-Dawley ; Reproducibility of Results ; Suspensions ; Tissue Distribution ; Trachea
    • Abstract:
      The objective of this study was to perform the in vitro and in vivo validation of an endotracheal aerosolization (ETA) device (HRH MAG-4, HM). Solid lipid nanoparticle suspension (SLNS) formulations with particle sizes of approximately 120, 240, 360, and 480 nm were selected as model nanoparticle suspensions for the validation. The emission rate (ER) of the in vitro aerosolization and the influence of aerosolization on the physicochemical properties were investigated. A high ER of up to 90% was obtained, and no significant alterations in physicochemical properties were observed after the aerosolization. The pulmonary deposition of model drug budesonide in Sprague-Dawley rats was determined to be approximately 80%, which was satisfactory for pulmonary delivery. Additionally, a fluorescent probe with aggregation-caused quenching property was encapsulated in SLNS formulations for in vivo bioimaging, after excluding the effect of aerosolization on its fluorescence spectrum. It was verified that SLNS formulations were deposited in the lung region. The results demonstrated the feasibility and reliability of the HM device for ETA in laboratory investigation.
    • Contributed Indexing:
      Keywords: aerosolization device; aggregation-caused quenching; bioimaging; nanoparticle; pulmonary delivery
    • Accession Number:
      0 (Drug Carriers)
      0 (Fluorescent Dyes)
      0 (Lipids)
      0 (Suspensions)
      51333-22-3 (Budesonide)
    • Publication Date:
      Date Created: 20180926 Date Completed: 20190909 Latest Revision: 20191210
    • Publication Date:
      20221213
    • Accession Number:
      10.1021/acs.molpharmaceut.8b00668
    • Accession Number:
      30252486